(no title)
ryankemper | 4 years ago
First: does the rate at which the cells are made to artificially produce spike protein follow a different curve than the rate at which SARS-2 would? i.e. could mRNA vaccination cause a much more aggressive "inflammatory cliff", thus the huge percentage of "mild" adverse reactions (mild meaning, you feel like death for a day but end up fine with no detectable long-term issues)? It's possible.
And switching to efficacy, while personally I think resistance to the spike protein alone will be sufficient, because SARS-2 does not have the same ability to mutate/evolve the way Influenza does (for example, I can't imagine SARS-2 evolving away from the spike protein), it's very possible that the diverse epitopes produced by real SARS-2 infection give a much more robust and enduring immunity.
fastball|4 years ago
ryankemper|4 years ago